Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. pilot study

Journal of Sexual Medicine

Volumn 5, Issue 9, 2008, Pages 2170-2178

  Bechara, Amado ^a   Romano, Salomon ^a   Casabé, Adolfo ^a   Haime, Sergio ^a   Dedola, Pablo ^a   Hernández, Cecilia ^a   Rey, Horacio ^a  

^a HOSPITAL DURAND   (Argentina)

Author keywords

Benign prostatic hyperplasia; Erectile dysfunction; LUTS; PDE5 inhibitor

Indexed keywords

TADALAFIL; TAMSULOSIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EJACULATION DISORDER; GLOBAL ASSESSMENT QUALITY; HUMAN; HYPOTENSION; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PILOT STUDY; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; UROFLOWMETRY; VISUAL IMPAIRMENT;

EID: 51349092065     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2008.00940.x     Document Type: Article

References (43)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of benign prostatic hyperplasia with age. J Urol 1984;132:474-9.
2. Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, Lieber MM. The prevalence of prostatism: A population-based survey of urinary symptoms. J Urol 1993;150:85-9.
3. Girman CJ, Jacobsen SJ, Rhodes T, Guess HA, Roberts RO, Lieber MM. Association of health-related quality of life and benign prostatic enlargement. Eur Urol 1999;35:277-84.
4. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, Mckinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
5. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: Results of the "Cologne Male Survey. "Int J Impot Res 2000;12:305-11.
6. Laumann EO, West S, Glasser D, Carson C, Rosen R, Kang JH. Prevalence and correlates of erectile dysfunction by race and ethnicity among men aged 40 or older in the United States: From the male attitudes regarding sexual health survey. J Sex Med 2007;4:57-65.
7. Ahmed I, El-Sakka AI. Lower urinary tract symptoms in patients with erectile dysfunction: Analysis of risk factors. J Sex Med 2006;3:144-9.
8. Chitale S, Collins R, Hull S, Smith E, Irving S. Is the current practice providing an integrated approach to the management of LUTS and ED in primary care? An audit and literature review. J Sex Med 2007;4:1713-25.
9. Emberton M, Zinner N, Michel MC, Gittelman M, Chung M-K, Madersbacher S. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: Therapeutic options for the man at risk. BJU Int 2007;100:249-53.
10. McConnell JD, Roehrborn CG, Bautista OM, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA. Medical Therapy of Prostatic Symptoms (MTOPS) research group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98.
11. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alphareductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-41.
12. Hartmut P. Oral pharmacotherapy of erectile dysfunction (ED). In: Hartmut P, Buvat J, eds. Standard practice in sexual medicine. Chapter 7. Blackwell Publishing Ltd.; 2006:75-93.
13. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, Anglin G, Whitaker S. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses. J Urol 2002;168:1332-6.
14. Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E, Bandel T. The efficacy and tolerability of vardenafil, a new, oral, selective O1 phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: The first at-home clinical trial. Int J Impot Res 2001;13:192-9.
15. Padma-Nathan H, Eardley I, Kloner RA, Laties AM, Montorsi F. 4 year update on the safety of sildenafil citrate (Viagra®). Urology 2002;60(suppl2B):67-90.
16. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O'Leary MP, Puppo P, Robertson C, Giuliano F. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol 2003;44:637-49.
17. McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000;12(suppl 4): S6-S11.
18. Shiri R, Häkkinen J, Koskimäki J, Huhtala H, Auvinen A, Hakama M, Tammela TL. Association between the bothersomeness of lower urinary tract symptoms and the prevalence of erectile dysfunction. J Sex Med 2005;2:438-44.
19. Braun MH, Sommer F, Haupt G, Mathers MJ, Reifenrath B, Engelmann UH. Lower urinary tract symptoms and erectile dysfunction: Co-morbidity or typical "aging male"symptoms? Results of the "Cologne Male Survey. "Eur Urol 2003;44:588-94.
20. Costabile RA, Steers WD. How can we best characterize the relationship between erectile dysfunction and benign prostatic hyperplasia? J Sex Med 2006;3:676-81.
21. Khan MA, Thompson CS, Dashwood MR, Mumtaz FH, Morgan RJ, Mikhailidis DP. Endothelin-1 and nitric oxide in the pathogenesis of urinary tract disorders secondary to bladder outlet obstruction. Curr Vasc Pharmacol 2003;1:27-31.
22. Gradini R, Realacci M, Ginepri A, Naso G, Santangelo C, Cela O, Sale P, Berardi A, Petrangeli E, Gallucci M, Di Silverio F, Russo MA. Nitric oxide synthesis in normal and benign hyperplastic human prostate: Immunohistochemistry and molecular biology. J Pathol 1999;189:224-9.
23. Deedwania PC. Mechanisms of endothelial dysfunction in the metabolic syndrome. Curr Diab Rep 2003;3:289-92.
24. Yassin A, Saad F, Hoesl CE, Traish AM, Hammadeh M, Shabsigh R. Alphaadrenoreceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS-Implications for clinical practice. Andrologia 2006;38:1-12.
25. Bing W, Chang S, Hypolite JA, DiSanto ME, Zderic SA, Rolf L, Wein AJ, Chacko S. Obstruction induced changes in urinary bladder smooth muscle contractility: A role for Rho kinase. Am J Physiol Renal Physiol 2003;285:F990-F997.
26. Chang S, Hypolite JA, Zderic A, Wein AJ, Chacko S, Disanto ME. Increased corpus cavernosum smooth muscle tone associated with partial bladder outlet obstruction is mediated via Rho-kinase. Am J Physiol Regul Integr Comp Physiol 2005;289:R1124-R1130.
27. Schiff JD, Mulhall JP. The link between LUTS and ED: Clinical and basic science evidence. J Androl 2004;25:470-8.
28. Uckert S, Küthe A, Jonas U, Stief CG. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001;166:2484-90.
29. Tinel H, Stelte-Ludwig B, Hüter J, Sandner P. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006;98:1331-2.
30. McVary K, Camps J, Henry G, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized, double-blind trial. J Urol 2007;177:1071-7.
31. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J. Urol 2007;177:1401-7.
32. Mulhall JP, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006;3:662-7. Comment in: Eur Urol 2007;51:278.
33. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. J Sex Med 2006;3:662-7.
34. Mulhall JP, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006;3:662-7.
35. Oger S, Behr-Roussel D, Gorny D, Charles Tremeaux J, Combes M, Alexandre L, Giuliano F. Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum. J Sex Med 2008;5:935-45.
36. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007;51:1717-2.
37. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TLJ, Roehrborn C. Efficacy and safety of long-term treatment with 5a-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004;46:488-95.
38. Kloner R, Jackson G, Emmick J, Mitchell M, Bedding A, Warner L, Pereira A. Interaction between the phosphodiesterase 5 inhibitor. Tadalafil and 2 alfa-blockers, doxazosin and tamsulosin in Healthy normotensive men. J Urol 2004;172:1935-40.
39. Kloner R. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004;110:3149-55H Available at: http://circ.ahajournals.org/cgi/content/ full/110/19/3149 (accessed June 22, 2004).
40. DaHa on file. Food and Drug Administration. Available at: Viagra: http://www.fda.gov/cder/consumerinfo/viagra/vIAGRA.htm; Levitra: http://www.fda.gov/cder/drug/infopage/vardenafil/default.htm; Cialis: http://www.fda.gov/cder/drug/infopage/cialis/default.htm (accessed November 14, 2007).
41. McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med 2004;1:292-300.
42. Brock GB, Mcmahon CG, Chen KK, Costigan T, Shen W, WatkinsV Anglin G, Efficacy And Whitaker S. Safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses. J Urol 2002;168:1332-6.
43. Montorsi F, Verheyden B, Meuleman E, Junemann KP, Moncada I, Valiquette L, Casabe A, Pacheco C, Denne J, Knight J, Segal S, Watkins VS. Long-term safety and tolerability of thdalafil in the treatment of erectile dysfunction. Eur Urol 2004;45:339-45.